Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis

Inflammatory Bowel Diseases

Volumn 10, Issue 3, 2004, Pages 229-233

  Herrlinger, Klaus R ^a   Dittmann, Rike ^b   Weitz, Gunther ^b   Wehkamp, Jan ^a   Ludwig, Diether ^b   Schwab, Matthias ^c   Stange, Eduard F ^a   Fellermann, Klaus ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Crohn's disease; Disease activity; Procalcitonin; Self limited colitis; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CALCITONIN; HORMONE PRECURSOR; PROCALCITONIN;

ARTICLE; BACTERIAL INFECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; ENTERITIS; ENTEROCOLITIS; ENZYME IMMUNOASSAY; FECES CULTURE; HORMONE BLOOD LEVEL; HUMAN; IDIOPATHIC DISEASE; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MEASUREMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEROLOGY; ULCERATIVE COLITIS;

BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; COLITIS, ULCERATIVE; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; ENTEROCOLITIS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY;

EID: 2442630605     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200405000-00008     Document Type: Article

References (32)

1. Ludwig D, Stange EF. Treatment of ulcerative colitis. Hepatogastroenterology. 2000;47:83-89.
2. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology. 2000;118:S68-S82.
3. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330: 1841-1845.
4. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1998;93:1860-1866.
5. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet. 1997;349:521-524.
6. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337:1029-1035.
7. Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341:515-518.
8. Rau B, Steinbach G, Gansauge F, et al. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut. 1997;41:832-840.
9. Muller CA, Uhl W, Printzen G, et al. Role of procalcitonin and granulocyte colony stimulating factor in the early prediction of infected necrosis in severe acute pancreatitis. Gut. 2000;46:233-238.
10. Brunkhorst FM, Eberhard OK, Brunkhorst R. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med. 1999;27:2172-2176.
11. Hammer S, Meisner F, Dirschedl P, et al. Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Transpl Immunol. 1998;6:235-241.
12. Jaresova M, Striz I, Cermakova J, et al. Serum procalcitonin concentrations in transplant patients with acute rejection and bacterial infections. Immunol Lett. 1999;69:355-358.
13. Kuse ER, Langefeld I, Jaeger K, et al. Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med. 2000;28:555-559.
14. Gendrel D, Raymond J, Coste J, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J. 1999;18:875-881.
15. Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997;40:1250-1256.
16. Moosig F, Csernok E, Reinhold-Keller E, et al. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol. 1998;25:1531-1533.
17. Ludwig D, Wiener S, Bruning A, et al. Mesenteric blood flow is related to disease activity and risk of relapse in Crohn's disease: a prospective follow-up study. Am J Gastroenterol. 1999;94:2942-2950.
18. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35:231-235.
19. Linskens RK, van Bodegraven AA, Schoorl M, et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci. 2001;46:644-648.
20. Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology. 1992;102: 514-519.
21. Sturm A, Schulte C, Schatton R, et al. Transforming growth factor-beta and hepatocyte growth factor plasma levels in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:445-450.
22. Mahmud N, O'Connell MA, Stinson J, et al. Tumour necrosis factor-alpha and microalbuminuria in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1995;7:215-219.
23. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359-367.
24. Kornbluth A, Sachar DB, Salomon P. Crohn's disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease: Pathophysiology, Diagnosis, Management. Philadelphia: WB Saunders, 1998:1708-1734.
25. Jewell DP. Ulcerative colitis. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease: Pathophysiology, Diagnosis, Management. Philadelphia: WB Saunders, 1998:1735-1761.
26. Schumacher G. First attack of inflammatory bowel disease and infectious colitis. A clinical, histological and microbiological study with special reference to early diagnosis. Scand J Gastroenterol Suppl. 1993;198:1-24.
27. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
28. Truelove SC, Witts LJ. Cortisone in the treatment of ulcerative colitis. Final report of a therapeutic trial. Br Med J. 1955;2:1041-1048.
29. Mandal BK, Schofield PF, Morson BC. A clinicopathological study of acute colitis: the dilemma of transient colitis syndrome. Scand J Gastroenterol. 1982;17:865-869.
30. Surawicz CM, Belic L. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology. 1984;86:104-113.
31. Schumacher G, Kollberg B, Sandstedt B, et al. A prospective study of first attacks of inflammatory bowel disease and non-relapsing colitis. Microbiologic findings. Scand J Gastroenterol. 1993;28:1077-1085.
32. Wehkamp J, Harder J, Weichenthal M, et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2003;9:215-223.